Utilising peptides derived from healthy human gut microbiome, this technology offers potential therapeutic applications in treating disorders related to mood, behaviour, and gastrointestinal function by modulating the gut-brain axis.

Utilising peptides derived from healthy human gut microbiome, this technology offers potential therapeutic applications in treating disorders related to mood, behaviour, and gastrointestinal function by modulating the gut-brain axis.
Ryhan is a Junior Officer for Industry Partnerships & Commercialisation at Imperial’s Faculty of Natural Sciences. He holds an MChem degree in Chemistry w/. Medicinal Chemistry from Newcastle University and a Postgraduate Certificate in Intellectual Property from...
A nanoparticle drug platform that can deliver small molecule drugs over a sustained period in a stable, low-toxic manner.
An immunotherapy platform capable of enhancing the anti-tumour efficacy of invariant natural killer T cells (iNKT).
Novel lipid nanoparticles (LNPs) for targeted delivery of RNA-based vaccines and therapeutics, with improved long-term (12 months) thermostability at ambient temperatures (as high as 40 °C), in aqueous liquid or lyophilised form.
A cellular therapy to locally deliver nitric oxide (NO) to the conventional aqueous humour outflow pathway, thereby lowering eye pressure and preserving vision in glaucoma.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Aenean nec venenatis arcu. In fermentum non tellus nec vulputate. Integer accumsan, nunc sit amet porta commodo, diam sapien feugiat purus, at imperdiet arcu nisi quis dui. Etiam vel nisl sem. Proin felis nisl, fringilla eu eros ac, sodales pellentesque sem.